SR-9009
Stenabolic — REV-ERB Agonist and Circadian Modulator
01
Overview
SR-9009 (Stenabolic) is a synthetic REV-ERBα/β agonist developed at the Scripps Research Institute. REV-ERB proteins are core components of the circadian clock machinery. By activating these nuclear receptors, SR-9009 modulates circadian rhythm gene expression, resulting in profound effects on metabolism, inflammation, lipogenesis, and exercise capacity.
02
Mechanism of Action
SR-9009 activates REV-ERBα and β, nuclear heme receptors that form core repressive components of the circadian clock. This enhances mitochondrial biogenesis in skeletal muscle, increases BMAL1-mediated metabolic gene suppression, and reduces lipogenic and inflammatory gene expression.
03
Research Highlights
Scripps Institute research shows 50% increase in running capacity in untrained mice
Metabolic studies demonstrate increased oxygen consumption and energy expenditure without exercise
Atherosclerosis models show significant plaque reduction and improved lipid profiles
04
Dosage
Administration & Timing
Oral administration (capsule or solution), 2–3× daily due to short half-life. Research protocols administer morning, midday, and pre-exercise.
Dosage Guidelines
Cycle Length
4–8 weeks; research is preclinical.
05
Reconstitution
Solvent
Not applicable — orally dosed capsule or solution
Volume
N/A
Concentration
10–30 mg total daily dose
Storage
Store at room temperature (15–25 °C); protect from moisture.
Notes
SR-9009 (Stenabolic) is a REV-ERBα agonist with very poor oral bioavailability (~2%); multiple daily doses are required.
Research Reference Only
Dosage and reconstitution values reflect commonly cited ranges from published research literature and are presented for educational and research reference only. This is not medical advice or a dosing recommendation. HEXAGEN does not endorse human use of any compound. Always consult a qualified healthcare professional.
Research Disclaimer
SR-9009 is for educational and research purposes only. Not intended as medical advice. Consult a qualified healthcare professional before making any health-related decisions.
Related Compounds
View All
SR-9009 Knowledge Graph
Explore how SR-9009 connects to mechanisms, research goals, related compounds, research stacks, and scientific references. Drag nodes, zoom, and filter by type.
No nodes match the active filters.
SR-9009 — Common Research Questions
What is SR-9009?
SR-9009 (Stenabolic) is a synthetic REV-ERBα/β agonist developed at the Scripps Research Institute. REV-ERB proteins are core components of the circadian clock machinery. By activating these nuclear r... SR-9009 belongs to the Non-Peptide Research research category and is studied for its stenabolic — rev-erb agonist and circadian modulator.
How does SR-9009 work?
SR-9009 activates REV-ERBα and β, nuclear heme receptors that form core repressive components of the circadian clock. This enhances mitochondrial biogenesis in skeletal muscle, increases BMAL1-mediated metabolic gene suppression, and reduces lipogenic and inflammatory gene expression.
What are the key research benefits of SR-9009?
Metabolic rate increase and fat loss. Dramatic endurance improvement in research. Circadian rhythm modulation and sleep normalization. Anti-inflammatory effects via NF-κB suppression. Reduced cholesterol and triglyceride levels. Glucose metabolism improvement.
What is the molecular structure of SR-9009?
SR-9009 is a research compound in the Non-Peptide Research category. Detailed molecular structure data is being compiled. Refer to primary literature for structural analysis.
What does the research say about SR-9009?
Scripps Institute research shows 50% increase in running capacity in untrained mice Metabolic studies demonstrate increased oxygen consumption and energy expenditure without exercise Atherosclerosis models show significant plaque reduction and improved lipid profiles These findings are based on preclinical and clinical research. SR-9009 is a research compound and these studies do not constitute medical advice.
Is SR-9009 FDA approved?
No. SR-9009 is not FDA-approved for any indication. It is a research chemical studied in preclinical and early clinical research. These compounds are not approved for human therapeutic use and should only be studied in appropriate research settings.
What category does SR-9009 belong to?
SR-9009 belongs to the Non-Peptide Research category, which focuses on selective androgen receptor modulators and other novel research compounds studied for their unique pharmacological profiles. You can explore more compounds in this category on the Non-Peptide Research pillar page.
Related Articles
RAD-140 (Testolone): Selective Anabolic Activity
Examining RAD-140's tissue-selective androgen receptor binding and its Phase I breast cancer research.
Cardarine (GW501516): PPARδ and Exercise Mimetics
How Cardarine activates PPARδ to drive fatty acid oxidation and its implications for endurance research.
LGD-4033 (Ligandrol): Phase I Clinical Data
Viking Therapeutics' Phase I trial showing dose-dependent lean mass gains and the VK5211 hip fracture study.
Scientific References
Solt et al. — "Stenabolic: REV-ERB agonist" (Nature, 2012)
Scripps Research Institute — Endurance and metabolic studies
Scripps Institute research shows 50% increase in running capacity in untrained mice
Metabolic studies demonstrate increased oxygen consumption and energy expenditure without exercise
Atherosclerosis models show significant plaque reduction and improved lipid profiles